BACKGROUND
Folate receptor alpha (FRα) is overexpressed in most high-grade ovarian cancers (HGOC), but use of the FRα-targeting drug mirvetuximab soravtansine-gynx (MIRV) is limited by expression-level restrictions and toxicity profile. Sofetabart mipitecan (Sofe-M) is a novel FRα-targeting antibody-drug conjugate desi...
I. Ray-Coquard, D. O'Malley, A. Oaknin et al.· Annals of Oncology· 0 citations
BACKGROUND
The management of metastatic castration-resistant prostate cancer (mCRPC) after progression on androgen receptor pathway inhibitors (ARPI) and docetaxel presents a critical therapeutic choice between cabazitaxel and [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT). This review provides a comprehensive analy...
F. Mattana, E. Palesandro, Valentino Dragonetti et al.· Cancer Treatment Reviews· 0 citations
Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetu...
Davide Ciardiello, G. Martini, L. Boscolo Bielo et al.· The journal of liquid biopsy· 0 citations
The biological function of p53, its role in EGFR-mutant lung cancer, and the implications for current and future therapies are discussed, and a timely and cohesive synthesis of a rapidly evolving field is offered.
J. Etessami, I. Attili, P. T. Aliaga et al.· Cancer Treatment Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.